年轻卒中患者中不确定潜能克隆性造血的发生率及其治疗意义
该研究对248例18至60岁急性脑缺血患者进行56个血液肿瘤相关基因的靶向测序,发现51例(21%)存在不确定潜能克隆性造血(CHIP),为一般人群的3倍;11例(4.4%)受邀进一步血液学评估,其中7例诊断为高风险CHIP,2例新诊断为骨髓增殖性肿瘤并有指征接受降细胞治疗。
要点
- 年轻卒中患者CHIP患病率为21%,约为一般人群的3倍。
- CHIP患者年龄更大、颈动脉内膜中层厚度更高、动脉粥样硬化负荷更高。
- 基因筛查在4.4%和1%的患者中分别识别出高风险CHIP和既往隐匿的骨髓增殖性肿瘤。
核心结论
- 在病因多未确定的年轻卒中患者中,CHIP患病率约为一般人群的3倍,基因筛查具有诊断和治疗价值。
- 高风险CHIP和既往隐匿的骨髓增殖性肿瘤分别在4.4%和1%的患者中被识别为潜在卒中病因。
- 未来研究应探讨CHIP在卒中复发和最佳二级预防中的作用。
研究设计与样本
- 前瞻性队列研究,纳入248例18至60岁急性脑缺血患者,对56个血液肿瘤中反复突变的基因进行靶向测序。
- CHIP患病率与来自Nijmegen Biomedical Study(n=1604)和UK Biobank(n=101678)的年龄匹配健康对照进行比较。
- 疑似高风险CHIP或骨髓增殖性肿瘤的患者受邀接受进一步血液学评估。
主要发现
- 248例患者中176例(71%)为隐源性卒中,51例(21%)存在CHIP。
- CHIP患病率在Nijmegen Biomedical Study中为7.7% vs 2.6%,在UK Biobank中为11.9% vs 4.1%,两项比较均P<0.001。
- CHIP患者年龄中位数53(50-59)岁 vs 51(41-56)岁,P<0.001;颈动脉内膜中层厚度0.68(0.58-0.80)mm vs 0.59(0.51-0.73)mm,P=0.009;动脉粥样硬化负荷29.4% vs 16.7%,P=0.04。
- 11例(4.4%)受邀进一步血液学评估,其中7例诊断为高风险CHIP,2例新诊断为骨髓增殖性肿瘤并有降细胞治疗指征。
关键数值与推荐
- CHIP在年轻卒中患者中的患病率为21%(51/248),在Nijmegen Biomedical Study对照中为2.6%,在UK Biobank对照中为4.1%。
- 高风险CHIP在4.4%的患者中被识别,既往隐匿的骨髓增殖性肿瘤在1%的患者中被识别。
临床怎么用
- 对病因多未确定的年轻卒中患者可考虑进行髓系疾病基因筛查,以识别高风险CHIP或隐匿性骨髓增殖性肿瘤。
- 疑似高风险CHIP或骨髓增殖性肿瘤的患者可转诊进行进一步血液学评估。
局限性
- 未来研究应探讨CHIP在卒中复发和最佳二级预防中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Undetermined stroke etiology hampers optimal secondary prevention in a large proportion of young patients. We explored whether genetic screening for clonal hematopoiesis of indetermined potential (CHIP), a novel risk factor for stroke, could identify patients with myeloid precursor lesions or covert myeloid neoplasm requiring specific treatment. METHODS: We performed targeted sequencing on 56 genes recurrently mutated in hematologic neoplasms in a prospective cohort of patients with acute brain ischemia between 18 and 60 years. CHIP prevalence was compared with age-matched healthy controls from the Nijmegen Biomedical Study (n=1604) and the UK Biobank (n=101 678). Patients with suspicion of high-risk CHIP or myeloid neoplasm were invited for further hematologic evaluation. RESULTS: We included 248 consecutive patients (39% women) of whom 176 (71%) had cryptogenic stroke etiology. Fifty-one (21%) patients had CHIP, 3-fold more than in the general population (7.7% versus 2.6% for the Nijmegen Biomedical Study and 11.9% versus 4.1% for UK Biobank; P<0.001 for both). Patients with CHIP were older (median [interquartile range], 53 [50-59] versus 51 [41-56] years; P<0.001), had higher carotid intima-media thickness (0.68 [0.58-0.80] versus 0.59 [0.51-0.73] mm; P=0.009), and had higher burden of atherosclerosis (29.4% versus 16.7%; P=0.04). We invited 11 patients (4.4%) for further hematologic assessment, which in 7 led to the diagnosis of high-risk CHIP and in 2 to the new diagnosis of a myeloproliferative neoplasm with indication for cytoreductive therapy. CONCLUSIONS: Using genetic screening for myeloid disorders in patients with stroke of predominantly undetermined etiology, we found a 3-fold higher CHIP prevalence than in the general population. We identified high-risk CHIP and previously covert myeloproliferative neoplasms as potential stroke etiologies in 4.4% and 1% of patients, respectively. Our findings demonstrate the diagnostic and therapeutic yield of genetic screening in young patients with stroke. Future studies should investigate the role of CHIP for stroke recurrence and optimal secondary prevention.
引用
- Mayerhofer E, Strecker C, Becker H, et al. Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke. Stroke. 2023. PMID: 36789775. doi:10.1161/STROKEAHA.122.041416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。